FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Science & Research
6

Evidence-Based Look at Wegovy

Pax Carey·6 months ago
Evidence-based assessment of Wegovy — what the data supports and where we need more information. Level of evidence summary: Strong evidence (multiple RCTs or meta-analyses): Wegovy improves specific biomarkers related to its mechanism of action. Moderate evidence (single RCT or consistent observational data): improvements in functional outcomes related to recovery and tissue health. Weak evidence (case reports, preclinical only): some of the broader health claims circulating online. The preclinical-to-clinical translation for Wegovy has actually been better than average for the peptide therapeutics space. Effects seen in animal models have generally been reproducible in humans, though with expected reductions in magnitude. I want to highlight the dose-response relationship because it is important for practical application. The available data suggests a sigmoidal dose-response curve with a clear minimum effective dose and a plateau beyond which additional dose provides minimal additional benefit. This means more is not necessarily better, and the commonly discussed dose ranges appear to be well-positioned on the dose-response curve. Future research directions that I find most exciting include biomarker-guided dosing (personalizing the protocol based on individual response markers) and combination protocols that leverage mechanistic synergies between Wegovy and complementary compounds. The science is solid. Let us keep the discussion grounded in what it actually shows.

Comments (7)

Sol DelgadoDEMO·6 months ago

Solid protocol. One suggestion: consider adding HRV tracking if you are not already. It has been the most objective and responsive metric for me during my Wegovy protocol. Changes in HRV preceded subjective improvements by about a week, which gave me early confidence the protocol was working.

3
Logan HarveyDEMO·6 months ago

Your point about consistency being more important than optimization really resonates. I wasted weeks early in my Wegovy journey tweaking doses and timing when I should have just picked a reasonable protocol and stuck with it. The best results came when I stopped overthinking and just stayed consistent.

4
Aria ConnollyDEMO·6 months ago

This is a great discussion about Wegovy. I want to add that I found morning dosing on an empty stomach gave me noticeably better results than evening dosing. Tried both for 4 weeks each. The difference was subtle but consistent across my tracking metrics.

5
Robin AshfordDEMO·6 months ago

Appreciate the evidence hierarchy approach. Too much of the peptide community treats anecdotal reports as equivalent to RCT data. They are both useful but for different purposes. Anecdotes generate hypotheses, RCTs test them.

0
Ashton WhitfieldDEMO·6 months ago

The sigmoidal dose-response with a clear minimum effective dose is useful practical info. For cost-conscious users this means finding the lowest effective dose saves money without sacrificing results. Have you identified where that inflection point is?

0
Sam BakerDEMO·6 months ago

The preclinical-to-clinical translation being better than average is encouraging. So many peptides show amazing results in rats and then underwhelm in humans. If Wegovy is maintaining effect sizes across species that bodes well for the clinical data we have.

0
Jesse AshfordDEMO·6 months ago

Combination protocols leveraging mechanistic synergies - can you elaborate on which complementary compounds you think pair well with Wegovy? I am particularly interested in whether stacking with anti-inflammatory peptides enhances outcomes.

0

Sign in to comment.